Oligonucleotide compounds comprising non-nucleotide overhangs
First Claim
1. A double-stranded nucleic acid molecule comprising a sense strand and an antisense strand, wherein the antisense strand comprises a non-nucleotide overhang covalently attached via a phosphodiester or a phosphorothioate linkage to the 3′
- or to the 2′
position of the sugar residue of the 3′
terminal nucleotide,wherein the non-nucleotide overhang is selected from the group consisting of C3Pi, C3Ps, C3Pi-C3OH, C3Pi-C3Pi, C3Pi-C3Ps, C3Ps-C3OH, C3Ps-C3Pi, C3Ps-C3Ps, C3Pi-C3Pi-C3OH, C3Ps-C3Ps-C3OH, C3Pi-C3Ps-C3OH, C3Ps-C3Pi-C3OH, C3Pi-C3Pi-C3Pi, C3Ps-C3Ps-C3Ps, C3Pi-C3Ps-C3Ps, C3Ps-C3Pi-C3Ps, C3Ps-C3Ps-C3Pi, C3Pi-C3Pi-C3Ps, C3Ps-C3Pi-C3Pi, C3Pi-C3Ps-C3Pi, C3Pi-rAb, C3Pi-dAb, C3Ps-rAb, C3Ps-dAb, rAbPi-C3OH, rAbPi-C3Pi, rAbPs-C3OH, rAbPs-C3Pi, dAbPi-C3OH, dAbPi-C3Pi, dAbPs-C3OH and dAbPs-C3Pi; and
wherein each Pi is a phosphodiester linkage and each Ps is a phosphorothioate linkage;
or a pharmaceutically acceptable salt of such molecule.
2 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to siRNA compounds comprising one non-nucleotide moiety covalently attached to at least one of the sense or antisense strands to down-regulate the expression of human genes. The invention also relates to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier and to methods of treating and/or preventing the incidence or severity of various diseases or conditions associated with the target genes and/or symptoms associated with such diseases or conditions.
50 Citations
22 Claims
-
1. A double-stranded nucleic acid molecule comprising a sense strand and an antisense strand, wherein the antisense strand comprises a non-nucleotide overhang covalently attached via a phosphodiester or a phosphorothioate linkage to the 3′
- or to the 2′
position of the sugar residue of the 3′
terminal nucleotide,wherein the non-nucleotide overhang is selected from the group consisting of C3Pi, C3Ps, C3Pi-C3OH, C3Pi-C3Pi, C3Pi-C3Ps, C3Ps-C3OH, C3Ps-C3Pi, C3Ps-C3Ps, C3Pi-C3Pi-C3OH, C3Ps-C3Ps-C3OH, C3Pi-C3Ps-C3OH, C3Ps-C3Pi-C3OH, C3Pi-C3Pi-C3Pi, C3Ps-C3Ps-C3Ps, C3Pi-C3Ps-C3Ps, C3Ps-C3Pi-C3Ps, C3Ps-C3Ps-C3Pi, C3Pi-C3Pi-C3Ps, C3Ps-C3Pi-C3Pi, C3Pi-C3Ps-C3Pi, C3Pi-rAb, C3Pi-dAb, C3Ps-rAb, C3Ps-dAb, rAbPi-C3OH, rAbPi-C3Pi, rAbPs-C3OH, rAbPs-C3Pi, dAbPi-C3OH, dAbPi-C3Pi, dAbPs-C3OH and dAbPs-C3Pi; and
wherein each Pi is a phosphodiester linkage and each Ps is a phosphorothioate linkage;or a pharmaceutically acceptable salt of such molecule. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)
-
3. The molecule of claim 2, wherein x=y=19.
-
4. The molecule of claim 2, wherein Z′
- is present.
-
5. The molecule of claim 2, wherein Z comprises a non-nucleotide overhang selected from the group consisting of C3Pi-C3OH, C3Pi-C3Pi, C3Pi-C3Ps, C3Ps-C3Pi, C3Ps-C3OH and C3Ps-C3Ps.
-
6. The molecule of claim 4, wherein Z′
- is a non-nucleotide overhang selected from the group consisting of C3OH, C3Pi and C3Ps, wherein Pi is a phosphodiester linkage and Ps is a phosphorothioate linkage.
-
7. A composition comprising the molecule of claim 1 or a pharmaceutically acceptable salt of such molecule, and a pharmaceutically acceptable carrier.
-
8. A method for treating a subject suffering from a disease or disorder associated with expression of a target gene comprising administering to the subject the molecule of claim 1 or a pharmaceutically acceptable salt of such molecule, in an amount effective to down-regulate expression of the target gene, thereby treating the subject.
-
9. The molecule of claim 1, wherein the non-nucleotide overhang is covalently attached to the 3′
- position of the sugar residue of the 3′
terminal nucleotide such that the 3′
terminal nucleotide has one of the following structures;
- position of the sugar residue of the 3′
-
10. The molecule of claim 1, wherein the non-nucleotide overhang is selected from the group consisting of C3Pi-C3OH, C3Pi-C3Pi, C3Pi-C3Ps, C3Ps-C3OH, C3Ps-C3Pi and C3Ps-C3Ps.
-
11. The molecule of claim 1, wherein the non-nucleotide overhang is selected from the group consisting of —
- C3Pi-C3Pi-C3OH, —
C3Ps-C3Ps-C3OH, —
C3Pi-C3Ps-C3OH, —
C3Ps-C3Pi-C3OH, —
C3Pi-C3Pi-C3Pi, —
C3Ps-C3Ps-C3Ps, —
C3Pi-C3Ps-C3Ps, —
C3Ps-C3Pi-C3Ps, —
C3Ps-C3Ps-C3Pi, —
C3Pi-C3Pi-C3Ps, —
C3Ps-C3Pi-C3Pi and —
C3Pi-C3Ps-C3Pi.
- C3Pi-C3Pi-C3OH, —
-
12. The molecule of claim 1, wherein the non-nucleotide overhang is selected from the group consisting of —
- C3Pi-rAb, —
C3Pi-dAb, —
C3Ps-rAb and —
C3Ps-dAb.
- C3Pi-rAb, —
-
13. The molecule of claim 1, further comprising a non-nucleotide overhang covalently attached to the 3′
- terminal nucleotide in the sense strand, wherein the non-nucleotide overhang covalently attached to the 3′
terminal nucleotide in the sense strand is selected from the group consisting of propanol, a C3 alkyl moiety linked to a phosphodiester and a C3 alkyl moiety linked to a phosphorothioate.
- terminal nucleotide in the sense strand, wherein the non-nucleotide overhang covalently attached to the 3′
-
14. The molecule of claim 13, wherein the non-nucleotide overhang covalently attached to the 3′
- terminal nucleotide in the sense strand is propanol; and
wherein the 3′
terminal sugar residue has the following structure;
- terminal nucleotide in the sense strand is propanol; and
-
15. The molecule of claim 13, wherein the non-nucleotide overhang covalently attached to the 3′
- terminal nucleotide in the sense strand is C3 alkyl moiety linked to a phosphodiester; and
wherein the 3′
terminal sugar residue has the following structure;
- terminal nucleotide in the sense strand is C3 alkyl moiety linked to a phosphodiester; and
-
16. The molecule of claim 13, wherein the non-nucleotide overhang covalently attached to the 3′
- terminal nucleotide in the antisense strand is selected from the group consisting of C3Pi-C3OH, C3Pi-C3Pi, C3Pi-C3Ps, C3Ps-C3OH, C3Ps-C3Pi and C3Ps-C3Ps; and
wherein each Pi is a phosphodiester linkage and each Ps is a phosphorothioate linkage.
- terminal nucleotide in the antisense strand is selected from the group consisting of C3Pi-C3OH, C3Pi-C3Pi, C3Pi-C3Ps, C3Ps-C3OH, C3Ps-C3Pi and C3Ps-C3Ps; and
-
17. The molecule of claim 16, wherein the non-nucleotide overhang covalently attached to the 3′
- terminal nucleotide in the antisense strand is C3Pi-C3OH; and
wherein the 3′
terminal sugar residue has the following structure;
- terminal nucleotide in the antisense strand is C3Pi-C3OH; and
-
18. The molecule of claim 16, wherein the non-nucleotide overhang covalently attached to the 3′
- terminal nucleotide in the antisense strand is C3Pi-C3Pi; and
wherein the 3′
terminal sugar residue has the following structure;
- terminal nucleotide in the antisense strand is C3Pi-C3Pi; and
-
19. The double stranded nucleic acid molecule of claim 2, wherein each of x and y is independently an integer between 18 and 27.
-
20. The double stranded nucleic acid molecule of claim 19, wherein x=y.
-
21. The double stranded nucleic acid molecule of claim 4, wherein Z′
- is a non-nucleotide overhang is selected from the group consisting of C3OH, C3Pi, C3Pi-C3OH, C3Pi-C3Pi, C3Pi-C3Ps, C3Ps, C3Ps-C3OH, C3Ps-C3Pi, C3Ps-C3Ps, C3Pi-C3Pi-C3OH, C3Ps-C3Ps-C3OH, C3Pi-C3Ps-C3OH, C3Ps-C3Pi-C3OH, C3Pi-C3Pi-C3Pi, C3Ps-C3Ps-C3Ps, C3Pi-C3Ps-C3Ps, C3Ps-C3Pi-C3Ps, C3Ps-C3Ps-C3Pi, C3Pi-C3Pi-C3Ps, C3Ps-C3Pi-C3Pi, C3Pi-C3Ps-C3Pi, C3Pi-rAb, C3Pi-dAb, C3Ps-rAb, C3Ps-dAb, rAbPi-C3OH, rAbPi-C3Pi, rAbPs-C3OH, rAbPs-C3Pi, dAbPi-C3OH, dAbPi-C3Pi, dAbPs-C3OH and dAbPs-C3Pi.
-
22. The double stranded nucleic acid molecule of claim 4, wherein Z′
- is an inorganic phosphate.
- or to the 2′
Specification